PeptideFactSheetsAn independent reference
Menu
Plain-English comparison

Peptides for recovery: what evidence exists?

What the evidence says about BPC-157, thymosin beta-4, CJC-1295, and ipamorelin for injury recovery.

Published by PeptideFactSheets. Sources and methods · Research reporting, not clinical review.

Overview

“Recovery” can mean tendon healing, wound repair, pain, return to activity, sleep, or muscle repair. A study measuring cells, rodents, or a hormone level may not answer any of those human questions.

BPC-157 and thymosin beta-4 are supported mainly by preclinical research for broad recovery claims. CJC-1295 and ipamorelin have limited human pharmacology data but no FDA-approved recovery use.

Side-by-side comparison

BPC-157
In clinical trialsMostly animal or lab research

Studied for

Acute hamstring strain in a registered Phase 2 trial · Tissue repair in animal models · Gastrointestinal effects in animal models

Thymosin beta-4
Not FDA approvedMostly animal or lab research

Studied for

Tissue and wound repair · Corneal healing · Cardiac repair

CJC-1295
Not FDA approvedEarly human evidence

Studied for

Growth hormone and IGF-1 levels · Pharmacology and tolerability

Ipamorelin
Not FDA approvedEarly human evidence

Studied for

Growth hormone release · Gastrointestinal motility · Postoperative ileus

Approved versus investigational

An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.

Research areas

  • Tissue-repair pathways in animal and laboratory models
  • Wound and corneal healing research
  • Growth-hormone signaling
  • Inflammation and cell migration

Risks

  • Animal healing signals do not prove faster or safer recovery in humans.
  • FDA has described evidence gaps and potential safety risks for these substances in compounding contexts.
  • Injury pain can signal a condition that needs diagnosis; masking or delaying care can create harm.

Open questions

  • Whether claimed effects translate to meaningful human recovery
  • Long-term safety, interactions, and uncommon adverse effects
  • Whether online products contain the claimed identity and strength

Questions to ask a healthcare professional

1. What is the diagnosis, and what is the usual recovery timeline?

2. Is the evidence from people with this injury or only from models?

3. What proven rehabilitation or treatment options exist?

4. Could this delay appropriate imaging, rehabilitation, or medical care?

Summary

Laboratory and animal findings do not establish human recovery benefits for these peptides.

ComparePeptides for skin and aging: research versus hypeEvidence for cosmetic peptides and systemic aging claims.CompareGrowth hormone pathway peptides comparedHow tesamorelin, sermorelin, CJC-1295, and ipamorelin differ in mechanism, status, and evidence.ComparePeptides for muscle growth and performance: what human evidence showsWhy growth-hormone signals, mitochondrial biology, and body-composition claims do not automatically prove more muscle, strength, recovery, or performance.

Sources

  1. fdaFDA: selected compounded-peptide safety risks

    FDA evidence-gap and product-quality concerns for BPC-157, CJC-1295, ipamorelin, and TB-500.

  2. clinical trialsClinicalTrials.gov: BPC-157 hamstring strain study

    Registered BPC-157 human study record; trial registration is not proof of clinical benefit.

  3. clinical trialsClinicalTrials.gov: CJC-1295 in HIV visceral obesity

    Registered CJC-1295 human study illustrating limited, non-recovery clinical context.

  4. pubmedIpamorelin postoperative ileus study

    Human proof-of-concept study outside broad injury-recovery claims.

  5. pubmedBPC-157 preclinical gastrointestinal review

    Preclinical evidence that cannot establish human recovery outcomes.